| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.06 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.077 | 0.06 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.091 | 0.06 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.088 | 0.07 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.07 |